Utilizing the Cunningham Panel in Clinical Practice

Webinar Chapters:
0:00 Utilizing the Cunningham Panel
4:40 Can infections really cause neuropsychiatric symptoms?
6:51 History of brain reactive antibodies
7:51 How does this occur biologically?
10:40 Study: brain inflammation and the basal ganglia
11:38 Connection between infections, immune system and brain function
15:50 Rheumatic fever triggered by strep
18:10 Molecular mimicry to strep and self-antigens
18:38 Infections associated with neuropsychiatric symptoms
25:32 Basal ganglia functions and PANS criteria connection
26:52 Biological targets in the Cunningham Panel
28:16 Case studies of Cunningham Panel patients
31:33 Dopamine receptors and symptom correlation
32:34 Tubulin and symptom correlation
33:48 Lysoganglioside GM1 and symptom correlation
34:27 CaMKII and its significance
38:15 Study review: Evaluation of the Cunningham Panel
43:00 Cunningham Panel ordering process
44:41 Overview of PANS/PANDAS diagnosis and treatment guidelines
51:54 Q&A
(This webinar aired January 25, 2023.)
The Cunningham Panel™ is an aid in a clinician’s diagnosis of autoimmune encephalopathy and basal ganglia encephalitis disorders.
Neurologic, psychiatric, and behavioral symptoms can result from a number of different etiologies. When the underlying root is an autoimmune encephalopathy or basal ganglia encephalitis, treatments that have shown effectiveness include anti-infectives, anti-inflammatory and immune modulatory modalities.
This complementary educational webinar will explain the clinical significance of autoimmune antibodies against brain and neuronal targets, and the types of symptoms that have been associated with them.
We will review some of the most common presenting symptoms associated with positive Cunningham Panel™ results, and share published clinical data on patients’ before and after effective treatment.